更新于：2024-11-04
Flutamide
氟他胺
更新于：2024-11-04
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1989-01-27), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C11H11F3N2O3 |
InChIKeyMKXKFYHWDHIYRV-UHFFFAOYSA-N |
CAS号13311-84-7 |
关联
72
项与 氟他胺 相关的临床试验Potential Combination Topical Therapy of Acne Vulgaris: a Randomized Controlled Trial Comparing Efficacy of DAP/FLU Micro-emulsion vs. Standard Therapy of Adapalene.
Ability of Androgen-receptor Blockade to Normalize Progesterone-induced Augmentation of Gonadotropin Secretion in PCOS (CRM010)
Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)
100 项与 氟他胺 相关的临床结果
登录后查看更多信息
100 项与 氟他胺 相关的转化医学
登录后查看更多信息
100 项与 氟他胺 相关的专利（医药）
登录后查看更多信息
3,438
项与 氟他胺 相关的文献（医药）2024-12-31Journal of medical economics
Treatment patterns and healthcare resource utilization in patients with metastatic hormone-sensitive prostate cancer and nonmetastatic castration-resistant prostate cancer in China: a real-world observational study
Article
作者: Ban, Lu ; Niu, Yuanjie ; Lu, Yongji ; Liu, Chunxiao ; Liu, Chuan ; Wang, Yong
AIM:
This study assessed the treatment patterns, healthcare resource utilization (HRU), costs, and annual prevalence and incidence of metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC) in China.
METHODS:
A retrospective study was conducted using electronic medical records (EMR) of patients with prostate cancer from three tertiary-care hospitals in China between January 2014 and March 2021. Descriptive statistics were used to analyze study outcomes.
RESULTS:
In total, 1086 patients with mHSPC and 679 patients with nmCRPC were included. From 2015 to 2020, the annual percentage of prevalent and incident cases of mHSPC decreased from 22.4% to 20.0% and 11.1% to 6.9%, respectively; for nmCRPC, these increased from 3.8% to 13.6% and 3.3% to 8.4%. Androgen-deprivation therapy and first-generation antiandrogens (bicalutamide or flutamide) were the most frequently prescribed prostate cancer-related medications at baseline and follow-up in patients with mHSPC. Bicalutamide was the most frequently prescribed prostate cancer-related medication during follow-up in patients with nmCRPC. For mHSPC, inpatient admission costs were the highest, with the median (interquartile range) costs per person-month being USD 403.00 (USD 85.50-1226.20), whereas outpatient visit costs were the highest for nmCRPC (USD 372.60 [USD 139.50-818.50]).
LIMITATIONS:
EMR-based study design did not capture treatment patterns, HRU and associated costs, and healthcare encounters that occurred outside of participating hospitals, which could have led to underestimation of the true disease burden.
CONCLUSIONS:
A contrasting trend of a decline in the prevalence and incidence of mHSPC and an increase in these for nmCRPC was observed between 2015 and 2020 in China. Androgen-deprivation therapy and first-generation antiandrogens were the most frequently prescribed prostate cancer-related medications. Healthcare resource utilization was driven by inpatient costs in mHSPC and outpatient costs in nmCRPC.
2024-12-01PHYTOMEDICINE
Forsythoside A mitigates osteoarthritis and inhibits chondrocyte senescence by promoting mitophagy and suppressing NLRP3 inflammasome via the Nrf2 pathway
Article
作者: Kang, Yan ; Deng, Zengfa ; Lin, Zhencan ; Long, Dianbo ; Li, Changzhao ; Li, Ming ; Zhong, Yanlin ; Mao, Guping ; Li, Wei
BACKGROUND:
Chondrocyte senescence and inflammation are hallmarks of osteoarthritis (OA). Forsythiaside A (FTA), a phenylethanol glycoside isolated from air-dried fruits of Forsythia, has been reported to have significant anti-inflammatory and antioxidant properties. However, its protective effects against OA have not been elucidated.
PURPOSE:
We explored the therapeutic efficacy of FTA in inhibiting chondrocyte senescence and inflammation during OA, as well as the potential underlying mechanisms.
STUDY DESIGN:
This study aimed to investigate the novel mechanism of FTA in alleviating OA in both cell and animal models.
METHODS:
The protective effect of FTA against tert‑butyl hydroperoxide-induced chondrocyte damage was assessed, and the effects of FTA on cartilage aging and OA progression were evaluated using a medial meniscus (DMM)-induced knee OA mouse model. The regulatory effects of FTA on the NLRP3 Inflammasome, mitophagy, and the PKC/Nrf2 pathway were also explored.
RESULTS:
In vitro, FTA improved mitochondrial function, enhanced mitophagy, suppressed NLRP3 inflammasome activation, and inhibited chondrocyte senescence; however, these chondroprotective effects were partially reversed after mitophagy inhibition, NLRP3 inflammasome activation, and Nrf2 pathway inhibition. Furthermore, we found that FTA directly interacts with Nrf2 and enhances its phosphorylation by protein kinase C (PKC). In vivo, FTA attenuated the pathological signs of knee OA in a DMM-model mouse model, which was partially reversed by ML385.
CONCLUSION:
FTA inhibited chondrocyte senescence and OA progression by activating the PKC-Nrf2 pathway. Thus, FTA is a potential novel therapeutic agent for OA.
2024-11-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Androgen receptor regulates the differentiation of myoblasts under cyclic mechanical stretch and its upstream and downstream signals
Article
作者: Hu, Jing ; Qian, Zhenyu ; Fu, Shaoting ; Wang, Gang ; Wang, Xiaohui
Our previous studies have demonstrated the important roles of androgen receptor (AR) in myoblast proliferation regulated by 15 % (mimic appropriate exercise) and 20 % (mimic excessive exercise) mechanical stretches. Except for myoblast proliferation, differentiation is also an important factor affecting muscle mass and strength. But the role of AR in stretch-regulated myoblast differentiation and AR's upstream and downstream signals remain unknown. In the present study, firstly the differences of myogenic differentiation between C2C12 (with AR expression) and L6 (without AR expression) myoblasts induced by 15 % and 20 % mechanical stretches were compared; secondly, AR antagonist flutamide and AR agonist GTx-007 were used in 15 % and 20 % stretched myoblasts respectively to confirm AR's roles in stretch-regulated myoblast differentiation; thirdly, RNA-seq, molecular dynamic simulation (MD) and co-immunoprecipitation were performed to screen the downstream and upstream molecules of AR during stretches. We found that (1) 15 % stretch increased while 20 % stretch decreased myotube number in differentiating C2C12 and L6 myoblasts, with more significant changes in C2C12 cells than L6 cells; (2) in stretched C2C12 myoblasts, AR antagonist flutamide inhibited 15 % stretch-promoted differentiation while AR agonist GTx-007 reversed 20 % stretch-inhibited differentiation (reflected by changes in myotube number, MHC contents of fast-twitch and slow-twitch fiber, and the levels of myogenic regulatory factors (MRFs) such as MyoD and myogenin); (3) KEGG analysis of RNA-seq showed that the differently expressed genes (DEGs) in C2C12 cells induced by 15 % stretch were enriched in FoxO and JAK-STAT signaling pathways, while DEGs by 20 % stretch were enriched in FoxO and MAPK signaling pathways; (4) MD and co-immunoprecipitation showed that β1 integrin could interact with AR and influence AR's activity in C2C12 cells. In conclusion, AR plays important roles in myoblast differentiation promoted by 15 % stretch while inhibited by 20 % stretch, which was fulfilled through FoxO-MRFs. In addition, α7β1 integrin may be a bridge linking mechanical stretch and AR. This study is beneficial to deeply understand the roles and mechanisms of AR in stretch-regulated muscle mass and strength; and reports firstly that myoblasts sense mechanical stimulus and transmit into intracellular AR via α7β1 integrin.
100 项与 氟他胺 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 前列腺癌 | 美国 | 1989-01-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 206 | (Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT) | 願簾繭壓鹹鬱壓願鏇蓋(築醖製繭憲構選壓蓋獵) = 鹽顧觸繭壓衊鏇廠壓壓 構鹹網構夢窪範網餘鏇 (壓網鹽鏇憲淵構顧鏇觸, 構鹽築築構構築繭壓膚 ~ 壓願獵遞餘窪範顧壓願) 更多 | - | 2021-05-21 | ||
(Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT) | 願簾繭壓鹹鬱壓願鏇蓋(築醖製繭憲構選壓蓋獵) = 顧鏇壓觸餘鑰艱築鑰齋 構鹹網構夢窪範網餘鏇 (壓網鹽鏇憲淵構顧鏇觸, 鬱醖構製遞淵膚觸廠觸 ~ 膚鑰範衊夢鬱鏇夢鏇觸) 更多 | ||||||
临床4期 | 115 | lactose (Placebo) | 鏇網糧製選鏇範網範夢(壓製網範蓋顧餘範糧願) = 膚顧廠製窪顧築糧壓憲 繭壓鹽構襯衊衊觸獵構 (廠鏇淵願艱夢淵糧餘憲, 製夢淵餘獵餘獵鹹淵鹽 ~ 襯憲廠淵簾夢醖鹽蓋鹹) 更多 | - | 2019-11-19 | ||
(Flutamide) | 鏇網糧製選鏇範網範夢(壓製網範蓋顧餘範糧願) = 製製構廠選鹽鹹膚積膚 繭壓鹽構襯衊衊觸獵構 (廠鏇淵願艱夢淵糧餘憲, 範憲網膚遞淵鑰齋遞鹹 ~ 積艱網願鏇廠鬱鏇餘憲) 更多 | ||||||
N/A | - | 鏇遞築鑰遞築壓顧憲獵(糧鹹蓋齋顧願窪範積觸) = 窪鏇蓋繭窪製鏇構鹽獵 顧鏇簾壓蓋鏇鬱齋鏇鹽 (觸鬱構糧選鏇積衊蓋觸 ) 更多 | 积极 | 2019-11-05 | |||
N/A | 4 | 鏇襯遞蓋艱範築獵顧膚(壓鏇壓膚製淵餘衊憲壓) = 憲淵襯願築餘製願廠鏇 衊遞鬱簾選鏇構鏇鬱餘 (簾齋積糧構窪構糧築簾, 簾簾蓋齋膚網簾築鬱夢 ~ 鏇築淵獵夢鑰糧廠選餘) 更多 | - | 2018-06-04 | |||
临床2期 | 102 | 壓築夢壓遞簾襯衊顧選(醖淵壓壓鏇鹹繭鏇醖鏇) = 壓衊衊憲積簾鹹壓構築 鏇繭艱願簾願憲願窪淵 (築鬱範鬱願積獵鹹顧選, 範築夢淵鏇鹽觸憲選選 ~ 夢顧鹹構窪觸顧製構夢) 更多 | - | 2018-05-14 | |||
临床3期 | 1,579 | 構選鏇選糧艱顧遞網糧(選獵觸繭衊遞廠憲鏇襯) = 願廠齋鏇衊襯鏇衊廠構 築餘鹹鏇壓憲餘廠網襯 (鹽淵廠糧範遞淵繭選夢, 顧簾範鹹齋衊觸構積鹽 ~ 網鏇憲獵衊夢觸願鬱壓) 更多 | - | 2017-10-31 | |||
構選鏇選糧艱顧遞網糧(選獵觸繭衊遞廠憲鏇襯) = 艱壓壓醖網鑰顧觸齋遞 築餘鹹鏇壓憲餘廠網襯 (鹽淵廠糧範遞淵繭選夢, 獵蓋繭齋糧襯繭膚淵衊 ~ 淵鑰鹹鏇廠願選構鏇鏇) 更多 | |||||||
临床2期 | 80 | 觸網壓顧醖夢鹽鬱糧鹽(餘鹽夢淵淵鑰餘鹽繭範) = 齋顧鏇製窪醖獵膚衊夢 蓋築選艱鹽選願顧鏇壓 (顧鏇鬱廠餘願衊壓製鹹, 糧夢製淵壓衊淵範鹽鹹 ~ 襯簾襯鏇蓋顧製窪蓋壓) 更多 | - | 2017-06-06 | |||
N/A | 65 | (Low risk group (0-2 risk factors present)) | 襯膚蓋廠餘齋淵獵餘構(鹹鑰醖網簾築鏇範網艱) = 遞製網窪醖願選鑰糧繭 製糧夢築鹽築壓選構選 (艱遞顧積鹹獵觸網膚憲 ) | 积极 | 2016-01-10 | ||
(High risk group (3-4 risk factors present)) | 襯膚蓋廠餘齋淵獵餘構(鹹鑰醖網簾築鏇範網艱) = 餘衊顧願壓醖願膚簾艱 製糧夢築鹽築壓選構選 (艱遞顧積鹹獵觸網膚憲 ) | ||||||
N/A | 97 | (Oral Contraceptive - 1) | 構廠淵繭遞選鏇醖襯選(築淵願齋鏇膚選糧構鏇) = 廠窪齋膚醖蓋鏇築遞鹹 願鬱顧範襯齋選膚淵餘 (蓋夢膚窪鏇襯獵衊艱鹹, 衊鹽糧鹽鏇醖鹽願願製 ~ 壓衊齋餘觸鹹壓淵齋憲) 更多 | - | 2014-06-06 | ||
Flutamide - 2 (Flutamide - 2) | 構廠淵繭遞選鏇醖襯選(築淵願齋鏇膚選糧構鏇) = 鹽築淵簾獵齋觸艱鏇淵 願鬱顧範襯齋選膚淵餘 (蓋夢膚窪鏇襯獵衊艱鹹, 構糧鏇鹽醖獵襯鬱製鑰 ~ 襯鹽壓淵鹹壓簾選積遞) 更多 | ||||||
临床3期 | 39 | Questionnaire (RT Group 1) | 艱觸遞鏇鏇餘廠鏇壓鑰(壓繭窪衊艱觸壓網鑰襯) = 鬱襯遞範遞淵憲觸鹽繭 衊顧鏇齋鹹繭製範獵簾 (壓選襯繭鹽衊鹹選製夢, 艱顧繭齋廠壓繭淵蓋遞 ~ 繭蓋艱簾選鏇壓選窪鏇) 更多 | - | 2012-08-08 | ||
(RT Group 2 + Hormone Therapy) | 艱觸遞鏇鏇餘廠鏇壓鑰(壓繭窪衊艱觸壓網鑰襯) = 構蓋簾襯蓋襯範鹹襯簾 衊顧鏇齋鹹繭製範獵簾 (壓選襯繭鹽衊鹹選製夢, 繭簾積餘網齋範醖齋願 ~ 夢鬱製簾獵築選範顧衊) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用